Marlan Kay, MD
Neurology · Kirkland, WANPI 1619175155
Payments from drug & device makers
Across 51 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$232
- Merz Pharmaceuticals, LLC$184
- AbbVie$160
- Microvention, Inc.$80
- Novartis$76
- Acadia Pharmaceuticals Inc$71
- plus $538 from 16 others
What the payments were for
- Food & beverage$1,25093%
- Education$917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $232 |
| Merz Pharmaceuticals, LLC | 6 | $184 |
| AbbVie(2 entities) | 6 | $160 |
| Microvention, Inc. | 3 | $80 |
| Novartis | 4 | $76 |
| Acadia Pharmaceuticals Inc | 3 | $71 |
| Lilly USA, LLC | 3 | $63 |
| Sanofi | 2 | $52 |
| MDD US Operations, LLC | 1 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Octapharma USA, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| TG Therapeutics, Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Medtronic | 1 | $26 |
| UCB, Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $23 |
| CSL Behring | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Neurelis, Inc. | 1 | $14 |
How this compares
$1,341 in reported general payments places this provider in the 65th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $29,820 |
| Levetiracetam | 100 | $3,594 |
| Gabapentin | 41 | $1,399 |
| Atorvastatin Calcium | 81 | $1,268 |
| Cilostazol | 42 | $1,083 |
| Dalfampridine ErDalfampridine | 13 | $1,019 |
| ClopidogrelClopidogrel Bisulfate | 75 | $888 |
| Donepezil Hcl | 52 | $756 |
| Amlodipine Besylate | 72 | $743 |
| Lamotrigine | 30 | $698 |
| Losartan Potassium | 77 | $628 |
| Telmisartan | 20 | $557 |
| Lisinopril | 31 | $532 |
| Phenytoin Sodium Extended | 17 | $493 |
| Baclofen | 23 | $465 |
Paid to pharmacies, not to this prescriber.
Other neurology in Kirkland
- Pinky AgarwalKirkland$5.4M
- James BowenKirkland$2.3M
- Daniel BurdickKirkland$1M
- Jason PoonKirkland$934K
- Alida GriffithKirkland$511K
- James SongKirkland$273K
- Jennifer WittKirkland$108K
- Arash FazlKirkland$71K
- Jason AldredSpokane$9.5M
- David GreeleySpokane$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.